Bi-Weekly Weight Loss Injection Bofanglutide Arrives in India

• Indian pharma Lupin partners with China's Gan & Lee Pharma to launch weight loss drug Bofanglutide in India.
• Bofanglutide is a GLP-1 category drug, requiring only one injection every two weeks, unlike weekly alternatives.
• Fewer injections aim to improve patient adherence and ease of treatment, addressing needle phobia.
• Clinical data shows patients lost 4.3-6.5 kg, comparable to or exceeding other GLP-1 drugs like semaglutide.
• The launch is significant for India, battling rising obesity and diabetes, offering a new, convenient option.

Why It Matters: Lupin introduces Bofanglutide, a bi-weekly GLP-1 injection, offering a convenient weight loss solution for India.